Unequal Premarket Treatment Sometimes Valid, CDRH Ombudsman Says
This article was originally published in The Gray Sheet
Executive Summary
Device manufacturers with similar products are not always treated equally in the premarket review process, but there is usually a legitimate reason for the discrepancies, CDRH Ombudsman Les Weinstein said